Efficacy and safety of dulaglutide in patients with type 2 diabetes: A meta-analysis and systematic review

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Zhang, Lin ^a,b   Zhang, Mei ^a   Zhang, Yuwei ^a   Tong, Nanwei ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DULAGLUTIDE; EXENDIN 4; GLUCAGON LIKE PEPTIDE; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PEPTIDE; SITAGLIPTIN; VENOM;

ANALOGS AND DERIVATIVES; BLOOD; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; META ANALYSIS; METABOLISM; PATHOPHYSIOLOGY; PATIENT SAFETY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

BLOOD GLUCOSE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; GLUCAGON-LIKE PEPTIDES; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PATIENT SAFETY; PEPTIDES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECOMBINANT FUSION PROTEINS; SITAGLIPTIN PHOSPHATE; TREATMENT OUTCOME; VENOMS;

EID: 84953898275     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep18904     Document Type: Article

References (36)

1. Holst, J. J., Vilsbøll, T. & Deacon, C. F. The incretin system and its role in type 2 diabetes mellitus. Molecular and cellular endocrinology 297, 127-136 (2009).
2. Edwards, K. L., Stapleton, M., Weis, J. & Irons, B. K. An update in incretin-based therapy: A focus on glucagon-like peptide-1 receptor agonists. Diabetes technology & therapeutic 14, 951-967 (2012).
3. Li, N., Lu, J. & Willars, G. B. Allosteric modulation of the activity of the glucagon-like peptide-1 (glp-1) metabolite glp-1 9-36 amide at the glp-1 receptor. PloS one 7, e47936 (2012).
4. Meier, J. J. Glp-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nature review. Endocrinology 8, 728-742 (2012).
5. Glaesner, W. et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue ly2189265, an fc fusion protein. Diabetes/metabolism research and reviews 26, 287-296 (2010).
6. Barrington, P. et al. Ly2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes, obesity & metabolism 13, 434-438 (2011).
7. Barrington, P. et al. A 5-week study of the pharmacokinetics and pharmacodynamics of ly2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes, obesity & metabolism 13, 426-433 (2011).
8. Umpierrez, G. E. et al. The effects of ly2189265, a long-acting glucagon-like peptide-1 analogue, in a randomized, placebo-controlled, double-blind study of overweight/obese patients with type 2 diabetes: The ego study. Diabetes, obesity & metabolism 13, 418-425 (2011).
9. Grunberger, G. et al. Monotherapy with the once-weekly glp-1 analogue dulaglutide for 12 weeks in patients with type 2 diabetes: Dose-dependent effects on glycaemic control in a randomized, double-blind, placebo-controlled study. Diabetic medicine 29, 1260-1267 (2012).
10. Guerci, B. et al. Safety and efficacy of dulaglutide versus sitagliptin after 104 weeks in type 2 diabetes (award-5). Canadian journal of diabetes 37, S44-45 (2013).
11. Nauck, M. et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (award-5). Diabetes care 37, 2149-2158 (2014).
12. Umpierrez, G., Tofé Povedano, S., Pérez Manghi, F., Shurzinske, L. & Pechtner, V. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (award-3). Diabetes care 37, 2168-2176 (2014).
13. Wysham, C. et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (award-1). Diabetes care 37, 2159-2167 (2014).
14. Dungan, K. M. et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (award-6): A randomised, open-label, phase 3, non-inferiority trial. Lancet 384, 1349-1357 (2014).
15. Terauchi, Y., Satoi, Y., Takeuchi, M. & Imaoka, T. Monotherapy with the once weekly glp-1 receptor agonist dulaglutide for 12 weeks in japanese patients with type 2 diabetes: Dose-dependent effects on glycaemic control in a randomised, double-blind, placebo-controlled study. Endocrine journal 64, 949-959 (2014).
16. Eli Lilly and Company. A study in participants with type 2 diabetes mellitus (award-2). Clinicaltrials.gov. (2015). Available at: www.clinicaltrials.gov. (Accessed: 15 February, 2015).
17. Eli Lilly and Company. A study in participants with type 2 diabetes mellitus (award-4). Clinicaltrials.gov. (2014). Available at: www.clinicaltrials.gov. (Accessed: 15 February, 2015).
18. Eli Lilly and Company. A study of dulaglutide in japanese participants with type 2 diabetes mellitus. Clinicaltrials.gov. (2012). Available at: www.clinicaltrials.gov. (Accessed: 15 February, 2015).
19. Eli Lilly and Company. A study of ly2189265 in japanese participants with type 2 diabetes mellitus. Clinicaltrials.gov. (2014). Available at: www.clinicaltrials.gov. (Accessed: 15 February, 2015).
20. Workgroup on Hypoglycemia ADA. Defining and reporting hypoglycemia in diabetes: A report from the american diabetes association workgroup on hypoglycemia. Diabetes care 28, 1245-1249 (2005).
21. Monami, M., Marchionni, N. & Mannucci, E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: A meta-analysis of randomized clinical trials. European journal of endocrinology 160, 909-917 (2009).
22. Shyangdan, D. S., Royle, P. L., Clar, C., Sharma, P. & Waugh, N. R. Glucagon-like peptide analogues for type 2 diabetes mellitus: Systematic review and meta-analysis. BMC endocrine disorders 10, 20 (2010).
23. Esposito, K. et al. Glp-1 receptor agonists and hba1c target of < 7% in type 2 diabetes: Meta-analysis of randomized controlled trials. Current medical research and opinion 27, 1519-1528 (2011).
24. Cotugno, M. et al. Clinical efficacy of bariatric surgery versus liraglutide in patients with type 2 diabetes and severe obesity: A 12-month retrospective evaluation. Acta diabetologica 52, 331-336 (2015).
25. Eckel, R. H., Barouch, W. W. & Ershow, A. G. Report of the national heart, lung, and blood institute-national institute of diabetes and digestive and kidney diseases working group on the pathophysiology of obesity-associated cardiovascular disease. Circulation 105, 2923-2928 (2002).
26. Raccah, D., Gourdy, P., Sagnard, L. & Ceriello, A. Lixisenatide as add-on to oral antidiabetic therapy: An effective treatment for glycemic control with body weight benefits in type 2 diabetes. Diabetes/metabolism research and reviews 30, 742-748 (2014).
27. Astrup, A. et al. Safety, tolerability and sustained weight loss over 2 years with the once-daily human glp-1 analog, liraglutide. International journal of obesity 36, 843-854 (2012).
28. Monami, M., Dicembrini, I., Marchionni, N., Rotella, C. M. & Mannucci, E. Effects of glucagon-like peptide-1 receptor agonists on body weight: A meta-analysis. Experimental diabetes research 2012, 672658 (2012).
29. Pencek, R., Blickensderfer, A., Li, Y., Brunell, S. C. & Chen, S. Exenatide once weekly for the treatment of type 2 diabetes: Effectiveness and tolerability in patient subpopulations. International journal of clinical practice 66, 1021-1032 (2012).
30. Nikfar, S., Abdollahi, M. & Salari, P. The efficacy and tolerability of exenatide in comparison to placebo; a systematic review and meta-analysis of randomized clinical trials. Journal of pharmacy & pharmaceutical sciences 15, 1-30 (2012).
31. Sun, F. et al. Impact of glp-1 receptor agonists on major gastrointestinal disorders for type 2 diabetes mellitus: A mixed treatment comparison meta-analysis. Experimental diabetes research 2012, 230624 (2012).
32. Nauck, M. A. A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes care 36, 2126-2132 (2013).
33. Butler, P. C., Elashoff, M., Elashoff, R. & Gale, E. A. A critical analysis of the clinical use of incretin-based therapies: Are the glp-1 therapies safe? Diabetes care 36, 2118-2125 (2013).
34. Li, L. et al. Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: Systematic review and meta-analysis of randomised and non-randomised studies. Bmj. 348, g2366 (2014).
35. Monami, M., Dicembrini, I., Nardini, C., Fiordelli, I. & Mannucci, E. Glucagon-like peptide-1 receptor agonists and pancreatitis: A meta-analysis of randomized clinical trials. Diabetes research and clinical practice. 103, 269-275 (2014).
36. DeKoven, M., Lee, W. C., Bouchard, J., Massoudi, M. & Langer, J. Real-world cost-effectiveness: Lower cost of treating patients to glycemic goal with liraglutide versus exenatide. Advances in therapy. 31, 202-216 (2014).